Home > Insider Trading > Filing (0000899243-21-009370)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1661998	Homology Medicines Inc.	FIXX	Pharmaceutical Preparations (2834)	473468154

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1754067	P Timothy Kelly	C/O Homology Medicines, Inc. One Patriots Park Bedford MA 01730	See Remarks.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-01	2,000	$6.63	4,232	No	4	M	Direct
Common Stock	Acquisiton	2021-03-01	2,000	$2.89	6,232	No	4	M	Direct
Common Stock	Acquisiton	2021-03-01	6,232	$11.16	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Options	Disposition	2021-03-01	2,000	$0.00	2,000	$6.63
Common Stock	Employee Stock Options	Disposition	2021-03-01	2,000	$0.00	2,000	$2.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
41,500		2027-12-06	No	4	M	Direct
32,001		2027-09-06	No	4	M	Direct

Footnotes

Includes 2,232 shares acquired under Issuer's Employee Stock Purchase Plan on February 26, 2021.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.9600 to $11.3100. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018, so that such option will become fully vested on January 1, 2022.
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was May 30, 2017.